CTLA4 and myeloid sarcoma: Next, we analyzed the expression value of CTLA-4 and PD-L1 in 40 peripheral blood mononuclear cell (PBMC) samples from RR-MS patients receiving various drugs, including Fingolimod, Interferon-beta 1-alpha (IFNβ-1α), Glatiramer acetate (GA), and Dimethyl fumarate (DMF), and compared their expression results with 5 naïve PBMC samples as well as 16 healthy donor PBMC.